Hepatic resection represents the first-line treatment for patients with resectable
hepatocellular carcinoma (HCC). However, the 5-year recurrence rates of HCC after surgery …

Hepatocellular carcinoma recurrence occurs in 40–70% of patients after hepatic resection.
Despite the high frequency of hepatocellular cancer relapse, there is no established …

Simple Summary Hepatocellular carcinoma (HCC) is the fifth most common cancer
worldwide and the second most common oncological reason for death. Liver resection and …

Background and Aims Transarterial chemoembolization (TACE) is a standard locoregional
therapy for patients with hepatocellular carcinoma (HCC) patients with a variable overall …

Immune-oncology based regimens have shown efficacy in advanced hepatocellular
carcinoma and have been implemented as standard of care as first line therapy. Their …

Hepatocellular carcinoma (HCC) is one of the most common types of malignancies in the
world, and most HCC patients undergoing liver resection relapse within five years …

Simple Summary Hepatocellular carcinoma (HCC) is the most common primary liver cancer,
comprising 90% of liver cancer cases worldwide, with a five-year survival rate of less than …

Simple Summary The role of postoperative transarterial chemoembolization (TACE) after
liver resection for hepatocellular carcinoma (HCC) remains unclear. We performed a …

Background To identify whether adjuvant transarterial chemoembolization (TACE) can
improve prognosis in HCC patients with a low risk of recurrence (tumor size≤ 5 cm, single …

Hepatocellular carcinoma (HCC) is one of the most lethal tumors in the world. Liver
resection (LR) and liver transplantation (LT) are widely considered as radical treatments for …